PHX Energy Announces Annual Meeting Voting Results for Election of Directors

CALGARY, Alberta, May 06, 2026 (GLOBE NEWSWIRE) -- PHX Energy Services Corp. ("PHX Energy") is pleased to announce the voting results for the election of directors at its annual meeting of shareholders held on May 6, 2026 ("the Meeting"). The following seven nominees were elected as directors of PHX Energy to serve until the next annual meeting of shareholders or until their successors are elected or appointed, with shares represented at the Meeting voting in favour of individual nominees as follows:

			FOR		WITHHELD
	Michael L. Buker		99.4%		0.6%
	Randolph M. Charron		98.1%		1.9%
	Karen David Green		99.6%		0.4%
	Terry D. Freeman		99.2%		0.8%
	Lawrence M. Hibbard		87.6%		12.4%
	John M. Hooks		98.4%		1.6%
	Myron A. Tétreault		98.0%		2.0%

About PHX Energy Services Corp.

PHX Energy is a growth oriented, public oil and natural gas services company. The Corporation, through its directional drilling subsidiary entities provides horizontal and directional drilling services to oil and natural gas exploration and development companies principally in Canada and the US. In connection with the services it provides, PHX Energy engineers, develops and manufactures leading-edge technologies. In recent years, PHX Energy has developed various new technologies that have positioned the Corporation as a technology leader in the horizontal and directional drilling services sector in North America.

The common shares of PHX Energy are traded on the Toronto Stock Exchange under the symbol "PHX".

For further information please contact:

PHX Energy Services Corp.
Michael Buker
President & Chief Executive Officer
Phone: (403) 543-4466

or

PHX Energy Services Corp.
Cameron Ritchie
Senior Vice President, Finance and Chief Financial Officer
Phone: (403) 543-4466

or

visit our website at www.phxtech.com

Source: PHX Energy Services Corp.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
• Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts 
• Autodesk commits $350 million to prepare the next generation for the AI jobs that design and make the physical world